We no longer support this browser. Using a supported browser will provide a better experience.

Please update your browser.

Close browser message

Treasury and Payments

Improve your working capital, reduce fraud and minimize the impact of unexpected disruptions with our treasury solutions—from digital portals to integrated payables and receivables—all designed to make your operations smoother and more efficient.

Learn more about our treasury solutions:

Credit and Financing

Prepare for future growth with customized loan services, succession planning and capital for business equipment or technology.

Learn more about our credit and financing solutions:

Commercial Real Estate

Get the strategic support to be successful throughout market and real estate cycles with insights, hands-on service, comprehensive financial solutions and unrivaled certainty of execution.

Learn more about our commercial real estate solutions:

International Banking

Global opportunities mean global challenges. But real success means understanding the local markets you serve—which is why we bring the business solutions, insights and market perspective you need. 

Learn more about our international banking solutions:

Newsletter

Discover the latest numbers, news and market moves to know about each week with Ginger Chambless, Commercial Banking’s Head of Research.

Life Sciences

Midyear 2022: Life sciences deals return to pre-pandemic levels

Our Biopharma and Medtech Deals and Venture Outlook offers a midyear look at upfront cash, IPOs, potential acquisitions and other trends.


Following years of record-breaking activity, biopharma and medtech dealmaking continued to see declines across its subsectors in the second quarter of 2022.

J.P. Morgan’s Biopharma and Medtech Deals and Venture Outlook report examines the sector at midyear to provide insights on industry trends we might see for the remainder of 2022. The report, powered by DealForma, highlights:

  • Biopharma and medtech venture: Both decreased from 2021’s peak, but are still near the top of the 2017 to mid-2020 range.
  • Advanced therapies and manufacturing: Contract development and manufacturing remained the most active subsector in medtech, with greater shifts to cell and gene therapy programs in biopharma.

What does this mean for the rest of 2022?

  • PIPEs and later-stage rounds will likely see an uptick in activity as private funds deploy investments.
  • Clinical outcomes must impress across multiple programs to attract funding and meet patient needs.

Read the full report to get all the insights.

Technology and Disruptive Commerce Healthcare IPO Life Sciences Midyear Outlook Startups Credit and Financing

Get in Touch and Stay Informed

icon
Loading...